![](https://static.biospace.com/dims4/default/fefce94/2147483647/strip/true/crop/622x350+0+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F8d%2Ff5%2Faa58f180409db2b4d3dce5ccf6c9%2Fgsk.jpeg)
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy in Head-to-Head HIV Trial
GSK is challenging Gilead Sciences in the HIV treatment market. The pharma pitted its rival Dovato therapy against Gilead’s Biktarvy in a Phase IV study, sharing results at the AIDS 2024 congress in Munich this week. The trial showed Dovato is just as …